Sign Up Today and Learn More About Cyrus Biotechnology Stock
Invest in or calculate the value of your shares in Cyrus Biotechnology or other pre-IPO companies through EquityZen's platform.
Cyrus Biotechnology Stock (CYRB)
Cyrus Biotechnology builds software tools to accelerate basic research in biotech, pharma, and industrial biotechnology.
About Cyrus Biotechnology Stock
Founded
2014
Headquarters
Seattle, WA, US
Industries
Software, Science and Engineering, Health Care
Cyrus Biotechnology Press Mentions
Stay in the know about the latest news on Cyrus Biotechnology
Cyrus Biotechnology Announces Selection of CYR212 as Clinical Candidate for Chronic IgG-driven Autoimmune Disease Including Myasthenia Gravis and Immune Thrombocytopenia
biospace • Jan 09, 2025
Cyrus Biotechnology Announces Selection of CYR212 as Clinical Candidate for Chronic IgG-driven Autoimmune Disease Including Myasthenia Gravis and Immune Thrombocytopenia
morningstar • Jan 09, 2025
Cyrus Biotechnology Announces Selection of CYR212 as Clinical Candidate for Chronic IgG-driven Autoimmune Disease Including Myasthenia Gravis and Immune Thrombocytopenia
businesswire • Jan 09, 2025
Synthetic Biology Market Worth $12.33 Billion in 2024, is Forecast to Generate Revenues of $31.52 Billion by 2029, Witnessing 20.6% CAGR
globenewswire • Dec 13, 2024
Cyrus Biotechnology reports preclinical data on IgG degrader
bioworld • Dec 12, 2024
Cyrus Biotechnology Management
Leadership team at Cyrus Biotechnology
Co-Founder & CTO
Javier Castellanos
Co-Founder & CEO
Lucas Nivon
Join now and verify your accreditation status to gain access to:
- Cyrus Biotechnology Current Valuation
- Cyrus Biotechnology Stock Price
- Cyrus Biotechnology Management
- Available deals in Cyrus Biotechnology and all other companies with relevant Deal Offering documents
- EquityZen's proprietary data and insights, which may include
- Cyrus Biotechnology Cap Table and Funding History by Share Class and Liquidity Preferences
- Cyrus Biotechnology Revenue and Financials
- Cyrus Biotechnology Highlights
- Cyrus Biotechnology Business Model
- Cyrus Biotechnology Risk Factors
- Cyrus Biotechnology Research Report from SACRA Research
Trading Cyrus Biotechnology Stock
How to invest in Cyrus Biotechnology stock?
Accredited investors can buy pre-IPO stock in companies like Cyrus Biotechnology through EquityZen funds. These investments are made available by existing Cyrus Biotechnology shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process here.
How to sell Cyrus Biotechnology stock?
Shareholders can sell their Cyrus Biotechnology stock through EquityZen's private company marketplace. EquityZen's network includes over 360K accredited investors interested in buying private company stock. Learn more about the easy and guided Shareholder process here.
If I invest, how do I exit my investment?
There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. More information on Express Deals can be found here and exit information can be found here.
Why choose EquityZen?
Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 46K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."
